Akeso and its partner Summit Therapeutics proclaimed on Tuesday that their high-profile PD-1xVEGF bispecific hit a major Phase 3 milestone outside of lung cancer.
Michelle Xia, Akeso CEO
August 26, 2026 07:02 AM EDT
R&DChina
Akeso, Summit hail ivonescimab's biliary tract cancer win in China-only Phase 3 trial
Reynald Castaneda
Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debate
China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial
Chinese cancer treatment shows survival edge in trial
Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint
Why Is Summit Therapeutics Stock Soaring Today? - Summit Therapeutics (NASDAQ:SMMT)
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
Fierce Pharma Asia—China's IIT scrutiny; Daiichi Sankyo, AZ ph. 3 win; Leo, Tanabe's dermatology deal
Fresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody…
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. |…
Akeso CEO Michelle Xia tells Endpoints the scrutiny of Chinese vs. Western patient data for ivonescimab is overblown, with the…
The biliary tract cancer trial is the latest breakthrough for Akeso’s ivonescimab, which has also shown promise in treating some…
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important…
